# **Special Issue**

## **Biomedicines:** 10th Anniversary

## Message from the Guest Editor

The year 2023 marks the 10th anniversary of *Biomedicines*, a peer-reviewed, open access journal containing research relevant to the field of biomedicine. To date, nearly 3000 papers have been published in Biomedicines, from more than 17000 authors, and 246 peer-reviewed articles have been cited 10 or more times (data up to 2 December 2021). We would like to sincerely thank our readers, innumerable authors, anonymous peer reviewers, editors, and all of the individuals who work for the journal in some way, and who have contributed time and effort throughout the years. These highlights would not have been possible without your participation. To celebrate this significant milestone, a Special Issue entitled "Biomedicines: 10th Anniversary" has been launched. This Special Issue will include high-quality papers on topics within the broad scope of *Biomedicines*. It is our pleasure to invite you to contribute an original research paper or a comprehensive review article on a current, trending topic for peer review and possible publication in Biomedicines.

#### **Guest Editor**

Prof. Dr. Shaker A. Mousa

 Retired, The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, NY 12144, USA

2. Vascular Vision Pharmaceuticals Co., Rensselaer Polytechnic Park, Troy, NY 12180, USA

### Deadline for manuscript submissions

closed (30 November 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/105389

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





## **About the Journal**

## Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).